Haicheung medicine "father to Son": Share price discount Half

No longer choose to reduce the company's shares in the two-tier market, Hai Xiang Pharmaceutical (002099), the original largest shareholder, founder Robonpeng decided to hand most of the stake in the bulk of the transfer of the sale to its son. Haicheung, 20th, said the Robonpeng to 464 million yuan of the total price of its 21.68% shareholding agreement to transfer to its son Rou, the latter is the company's chairman.　　Robonpeng still holds a 2.84% stake in the sea-Xiang pharmaceutical industry. Enterprises to the second generation of the announcement, September 17, Robonpeng and his son Rou signed the agreement on Equity transfer, the 34.8 million shares of its shares (21.68% of the total share capital) to Rou, to the agreement signed on the closing price of 50% as the transfer prices, That is, 13.325 yuan per share, the total transfer price is 464 million yuan.　　After the transfer, Rou will become the company's first major shareholder, holding 24.67% of the company's shares. "This should belong to the normal withdrawal and exit, the family business to the second generation."　　"One of the top ten shareholders of Hai Xiang Pharmaceutical industry said. Why only half of the day's closing price transfer? Haicheung Pharmaceutical Industry Dong Luo said the price is approved and approved by the regulatory authorities, but also by the exchange for approval, so there is no "sale" suspicion.　　September 21, Hai Xiang Pharmaceutical Gaokaigao walk, 27.32, Rose 5.2%.　　Continuous reduction in fact, from the beginning of this January, Hai Xiang Pharmaceutical major shareholders and their concerted action has been 7 consecutive reduction of the company's shares, a total of nearly 200 million yuan. September 2, Hai Xiang Pharmaceutical rights and interests of the report showed that, because of "their own capital needs", August 31, Robonpeng through the Shenzhen Stock Exchange bulk trading system to reduce the shares of 3.079 million shares of the company's total equity 1.92%, a set of 75.06 million yuan. September 7, 8th, Robonpeng also through the bulk trading platform separately reduce the 1 million shares and 1.121 million shares, the total set is 47.13 million yuan.　　In a short period of one week, Robonpeng is now over 120 million yuan. As a raw material pharmaceutical production enterprise, the main products of Hai Xiang Pharmaceutical is clindamycin, etc., in the first half of 2010, the company achieved total operating income of 515 million yuan, an increase of 24.7%, achieve net profit of 46.76 million yuan, an increase of 237%.　　Net profit for the three quarter is expected to increase by 280% to 310%. Robonpeng is the founder of Hai Xiang Pharmaceutical industry, the company was listed on December 26, 2006. April 19, 2009, Robonpeng resigned as a director and chairman of the company for reasons of age and physical health. March 26, 2008, Robonpeng son-in-law Zhengzhiguo resigned from the post of supervisor. December 30, 2009, Hai Xiang Pharmaceutical Industry Bulletin disclosed that Robonpeng and its concerted action Zhengzhiguo in the next 6 months through the securities trading system to sell the total share of the pharmaceutical industry 5% 8.6% of the equity.　　by June 30, 2010, Robonpeng and Zhengzhiguo had sold a total of 12.971 million shares, accounting for 8.08% of equity. ContinuousThe large shareholder's reduction lets the investor have the question to the company future business operation. In this respect, Luo said, and prior to the two-level market reduction, which is not the same as the nature of "equity treatment", because of the designated equity recipient, and with major shareholders have a special relationship, should be able to dissolve the investors before doubt. Compared with the two-tier market reduction, the transfer of the bulk equity is more beneficial to the stability of the company's equity structure and the stability of the management team.